


# Patient benefit through Roche's medicines

## Oncology Media Briefing, June 20 2006

*Andreas Abt, Deputy Head Roche Pharma  
Oncology*



# Simplified overview of cancer treatment



---


## **Cancer diseases and Roche's treatment options**

---

### **Roche's oncology development strategy**

# Breast cancer

- Most common cancer affecting women  
– more than 1 million new cases annually
- Survival rates high if diagnosed early
- HER2-positive breast cancer is a particularly aggressive form (~ 20-30% of all cases)
- HER2 testing of patients in the EU: 1/4 with early breast cancer still receive no testing



**Breast cancer as a proportion of all new cancers in women worldwide (2002)**

■ breast  
■ other

Source: GLOBOCAN 2002

# New hope for breast cancer patients



## Benefit from Herceptin in adjuvant therapy (HER2-positive breast cancer)

**Herceptin is expected to save over 10'000 lives per year worldwide when used in early stage breast cancer. It reduces the risk of death by one-third**

## Benefit from Avastin in 1st line therapy

**Women with advanced breast cancer can live twice as long without their cancer progressing if treated with Avastin**

Avastin breast cancer data filed in the US and to be filed in the EU later in 2006




„The feeling that I had regained control over my disease gave me a huge psychological lift“

Maggie Duke, 57, Herceptin patient

# Lung cancer

- Most common type of cancer in the world, with more than 1.2 million new cases every year
- NSCLC is most common form of lung cancer
- Although survival rates for early lung cancer are good, very few cases are diagnosed at this stage



**Lung cancer as a proportion of all new cancers occurring worldwide (2002)**

■ lung  
■ other

Source: GLOBOCAN 2002

# Breakthrough treatments in lung cancer



'I didn't think I would last a year but here I am, three and a half years on, living proof of the benefit of Tarceva.'

June Sheldon, 71, Tarceva patient

## Benefit from Avastin in 1st line therapy

**First medicine in a decade to show a survival benefit in previously untreated advanced NSCLC patients**

Avastin lung cancer data filed in the US and to be filed in the EU later in 2006


## Benefit from Tarceva in 2nd line therapy

**1 out of 3 advanced NSCLC patients treated with Tarceva are still alive one year after diagnosis compared to 1 out of 5 without the medicine.**

**In addition, their quality of life was improved.**

# Colorectal cancer (CRC)

- The second most common cancer in the developed world
- Advances in therapy for CRC have increased the five-year survival rate to 50%
- However, it is estimated that over 50% of people diagnosed with CRC will die



**CRC as a proportion of all new cancers occurring worldwide (2002)**

■ colorectal  
■ other

Source: GLOBOCAN 2002



# New options for colorectal cancer patients

## Benefit from Avastin in 1st line therapy

**Patients with metastatic CRC have a 50% greater chance of being alive if treated with Avastin plus chemotherapy than chemotherapy alone**

## Benefit from Xeloda in adjuvant therapy

**Around 4x less hospital visits if treated with Xeloda instead of intravenous chemotherapy. Xeloda can be taken at home.**



‘I was so pleased to get the all clear from my doctor and be able to return to work’

Hamish Hutchinson, 58, Avastin patient

# Non-Hodgkin's Lymphoma (NHL) – incidence is increasing substantially



,I have beaten the cancer, which is really down to the treatment I received – MabThera'

Adam Morris, 27, MabThera patient

## NHL

- NHL comprises most cancers that affect the lymphatic system
- The number of new cases of NHL has increased by 80% since 1970

## Benefit from MabThera

- **In treating aggressive NHL MabThera offers patients the best chance of a cure**
- **Maintenance therapy with MabThera in slowly developing indolent NHL halves the risk of death**



## Over 2 million patients have already benefited

Number of patients treated per product since launch (globally)

Xeloda	1,000,000
MabThera	730,000
Herceptin	310,000
Avastin	92,000
Tarceva	51,000

Source: Roche Statistics; April 2006



## **Cancer diseases and Roche's treatment options**

---

## **Roche's oncology development strategy**

---

# Our strategy: Setting new standards of care

*New tumor types, new combinations, new lines of intervention*


## Clinically differentiated product

target all current treatment combinations

target earlier (adjuvant) intervention

target all tumor types


Superior outcome for patients





# R&D timelines to develop a new cancer medicine

*Long time required to maximize drug potential*



# What we aim for

## *Expanding on a strong position*

**Avastin**

- Establish as backbone therapy in solid tumors

**Herceptin**

- Establish as the foundation of therapy for all HER2-positive breast cancer patients

**Tarceva**

- Move into 1st line and adjuvant NSCLC

**Xeloda**

- Establish combinations in CRC and move into early breast cancer

**MabThera**

- Establish maintenance therapy and move into leukemia

**Potential for combining targetted treatments and avoid chemotherapy (e.g. Avastin + Tarceva)**

# Appendix






# Current data securing mid-term growth

## *Assets on-hand to extend our leadership*

### launches

### data for future health authorities submissions



NB: Assuming normal approval process, barring unforeseen events



# A rich phase III pipeline targeting all main tumor types and early intervention

	ADJUVANT	MAINT.	1 <sup>st</sup> LINE		2 <sup>nd</sup> LINE		
Filed or to file soon	Herceptin adjuvant BC ✓	MabThera maintenance iNHL ✓	Tarceva pancreatic Ca ✓	Avastin NSCLC ✓			
			Avastin mBC ✓	Xeloda gastric Ca	Herceptin mBC combo hormonal		
Ongoing	Xeloda adjuvant BC	Tarceva & Avastin NSCLC maintenance	Avastin mCRC 1 <sup>st</sup> line ext.	Avastin mBC 1 <sup>st</sup> line ext.	Herceptin gastric Ca	Avastin mBC 2nd line	Xeloda mCRC 2nd line combo
	Xeloda adjuvant CC combo		Avastin RCC	MabThera 1 <sup>st</sup> line CLL		MabThera relapsed CLL	
	Avastin adjuvant BC		Avastin pancreatic Ca	Xeloda mCRC 1 <sup>st</sup> line combo		Avastin prostate Ca	
	Avastin adjuvant rectal Ca		Avastin ovarian Ca	Tarceva NSCLC 1 <sup>st</sup> line		Tarceva & Avastin NSCLC 2nd line	
To start soon	Tarceva adjuvant NSCLC						
	Avastin adjuvant NSCLC						
	Avastin adjuvant BC						